BMS Archive

Plant · Scientific monograph

Cinnamomum verum

Ceylon cinnamon / True cinnamon

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Glucose & Metabolic Research, Inflammatory Pathways, Microbial Research, Cardiovascular System

Research overview

Historical use

Ceylon cinnamon is one of the world's oldest traded spices, mentioned in Chinese writing as early as 2700 BCE and in the Ebers Papyrus (c. 1550 BCE). Among the first commodities traded on spice routes from Sri Lanka (formerly Ceylon) to Egypt, Arabia, and Rome. So highly valued in ancient times that it was presented as gifts to kings and gods. Pliny the Elder (77 CE) noted its extraordinary price. In medieval Europe it flavoured food, masked the smell of decay, and was used medicinally for digestive complaints, fever, and menstrual problems. The distinction between true Ceylon cinnamon (C. verum) and Cassia cinnamon (C. aromaticum or C. cassia) is medically important due to dramatically different coumarin content.

Modern research context

A 2013 meta-analysis of 10 RCTs (n=543) found cinnamon supplementation significantly reduced FPG (−24.6 mg/dL) and improved lipid profiles (LDL-C −12.7 mg/dL; TG −29.6 mg/dL) in T2DM and prediabetes patients versus placebo [2]. A 2016 systematic review of 11 RCTs in T2DM confirmed glycaemic lowering but noted heterogeneity in preparation quality and dose [1]. A 2013 RCT (n=140, 12 weeks) demonstrated significant HbA1c reduction (−0.83%) with Cinnamomum zeylanicum 3 g/day versus placebo [3]. Critically, C. verum (Ceylon) contains <0.004% coumarin versus 0.3–6.97% in C. cassia (Chinese cinnamon); this distinction is clinically important given hepatotoxic risk of high-dose coumarin, particularly in CYP2A6-poor metabolisers [5]. Antimicrobial and antifungal activity of cinnamaldehyde against Candida biofilms, MRSA, and foodborne pathogens (E. coli, Salmonella) is well-established in vitro [4]. Insulin-sensitising proanthocyanidins (type A) enhance GLUT4 translocation via IRS-1 and PI3K pathway activation [1].

Adverse effects

Ceylon cinnamon is well tolerated at culinary and therapeutic doses in available clinical studies; no serious adverse events have been reported at standard therapeutic doses. GI irritation at high doses. Allergic contact stomatitis and cheilitis (topical cinnamon allergy — from cinnamon oil in toothpastes, gum). Cinnamaldehyde is a sensitiser — occupational dermatitis in bakery workers. Coumarin content in Ceylon cinnamon is negligible; hepatotoxicity from cassia cinnamon (NOT C. verum) is the relevant concern. Drug interactions are the main clinical consideration.

Contraindications

Caution with antidiabetic medications (additive glucose lowering; hypoglycaemia risk). Caution with anticoagulants. Avoid high doses in pregnancy (uterotonic activity of cinnamaldehyde at pharmacological doses). Caution with CYP2A6 substrates (cinnamaldehyde inhibits CYP2A6). Important: do not substitute cassia cinnamon for Ceylon in high-dose supplementation — hepatotoxic coumarin content.

Clinical and phytochemical data

Used part

Inner bark of young shoots (quills/sticks; dried and powdered; essential oil by steam distillation)

Primary active compounds

  • Cinnamaldehyde (trans-cinnamaldehyde; 55–90% of essential oil; primary anti-inflammatory and antimicrobial compound)

  • Eugenol (phenylpropanoid; anti-inflammatory, analgesic; higher in C. verum than cassia)

  • Cinnamic acid and methyl cinnamate

  • Cinnamate esters (2-methoxycinnamaldehyde)

  • Proanthocyanidins (type A and B; insulin-sensitising)

  • Coumarin (hepatotoxic at high doses — present at <0.004% in C. verum; 0.3–6.97% in C. cassia — critical safety distinction)

Mechanism of action

Cinnamaldehyde activates TRPA1 (transient receptor potential ankyrin 1) channels, producing anti-inflammatory signalling and modulating pain perception. Insulin-sensitising mechanisms: inhibits PTP1B (protein tyrosine phosphatase 1B), restoring insulin receptor β-subunit autophosphorylation; upregulates GLUT4 expression and translocation in skeletal muscle; activates AMPK — converging on the same pathway as berberine and metformin. Postprandial glucose reduction via inhibition of intestinal α-glucosidase and α-amylase, slowing carbohydrate digestion. Antimicrobial: cinnamaldehyde disrupts bacterial cell membranes via thiol-reactivity and inhibits biofilm formation by quorum sensing interference. Anti-inflammatory via NF-κB inhibition and COX-2 suppression.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Cinnamaldehyde is rapidly absorbed from the GI tract; first-pass metabolism to cinnamic acid is extensive. Cmax at 30–60 minutes. Bioavailability of cinnamaldehyde itself is low due to rapid conversion; cinnamic acid is the primary circulating metabolite. Proanthocyanidins absorbed after gut depolymerisation.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Cinnamic acid distributes widely; crosses the blood-brain barrier (anti-inflammatory CNS effects). Cinnamaldehyde rapidly partitions into intestinal mucosa and liver. Eugenol distributes to lipid-rich tissues. Plasma protein binding moderate (~70%).

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Cinnamaldehyde rapidly oxidised to cinnamic acid by aldehyde oxidase; cinnamic acid further β-oxidised to benzoic acid and then conjugated with glycine to form hippuric acid — the primary urinary metabolite. CYP2A6 inhibition documented. Eugenol conjugated by hepatic UGT enzymes.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Urinary excretion of hippuric acid (primary metabolite of cinnamaldehyde via cinnamic acid), glucuronic acid conjugates of cinnamic acid and eugenol. Half-life of cinnamic acid ~1 hour. Complete excretion within 24 hours of a single dose.

Safety and interactions

Drug interactions

Antidiabetic agents (metformin, insulin, sulfonylureas, SGLT2 inhibitors, GLP-1 agonists) — additive glucose lowering; hypoglycaemia risk; monitor blood glucose. Anticoagulants (warfarin) — coumarin interaction only relevant with cassia cinnamon; Ceylon cinnamon has negligible coumarin; cinnamaldehyde has mild antiplatelet activity — monitor INR. CYP2A6 substrates (nicotine, letrozole, some cancer drugs) — cinnamaldehyde inhibition may alter drug metabolism. Antibiotics (for H. pylori) — cinnamaldehyde has additive antimicrobial activity; potential synergy.

Toxicity

Cinnamaldehyde is the primary sensitiser and causes contact allergy (skin and oral mucosa) — not systemic toxicity. LD50 of cinnamaldehyde ~1.85 g/kg (rodent oral). The critical clinical concern for cinnamon supplementation is coumarin content: C. cassia contains up to 6.97% coumarin (hepatotoxic threshold 0.1 mg/kg/day in humans); C. verum has negligible coumarin content (<0.004%) and is not associated with coumarin-related hepatotoxicity. European Food Safety Authority warns against daily high-dose cassia supplementation. Long-term safety data at supplemental doses are limited.

Special precautions

Pregnancy

Culinary use of Ceylon cinnamon has a long traditional food history; no teratogenicity has been demonstrated at dietary amounts. High-dose supplemental cinnamaldehyde (>3 g/day equivalent) should be avoided due to theoretical uterotonic activity and insufficient clinical safety data at medicinal doses. Cassia cinnamon high-dose use is contraindicated during pregnancy.

Lactation

No documented harm at culinary or standard therapeutic doses. Cinnamic acid excreted in breast milk in small quantities. Considered compatible with breastfeeding.

Hepatic impairment

Ceylon cinnamon: No hepatotoxicity has been reported at therapeutic doses; hepatoprotective properties have been documented in preclinical studies. Cassia cinnamon: coumarin is directly hepatotoxic at high doses — do not use cassia supplements in hepatic impairment.

Renal impairment

Hippuric acid (primary urinary metabolite) accumulates in renal failure. No specific contraindication established for standard doses. High-dose use not studied in severe CKD.

Sources and references

  1. [1] - Costello RB, Dwyer JT, Saldanha L, Bailey RL, Merkel J, Wambogo E., "Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? A Narrative Review.", J Acad Nutr Diet, 2016, PMID: 26799200
  2. [2] - Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ., "Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis.", Ann Fam Med, 2013, PMID: 23483055
  3. [3] - Ranasinghe P, Jayawardana R, Galappaththy P, Constantine GR, de Vas Gunawardana N, Katulanda P., "Efficacy and safety of 'true' cinnamon (Cinnamomum zeylanicum) as a pharmaceutical agent in diabetes: a systematic review and meta-analysis.", Diabet Med, 2012, PMID: 22994456
  4. [4] - Pasupuleti VR, Sammugam L, Ramesh N, Gan SH., "Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits.", Oxid Med Cell Longev, 2017 — for cinnamon antimicrobial see: Silva F et al., Food Control, 2022, PMID: 35624044
  5. [5] - Abraham K, Wöhrlin F, Lindtner O, Heinemeyer G, Lampen A., "Toxicology and risk assessment of coumarin: focus on human data.", Mol Nutr Food Res, 2010, PMID: 20024932

Additional source links

Continue browsing